ALLK: Rega marang dodolan Allakos Inc
Allakos Inc. faces a liquidity shortage threat and a dependence on external financing due to a lack of commercial products. The unpredictability of immune drug trials creates a risk of a price collapse in the event of negative test results. The ratio of cost to sales volume on this GURU.Markets chart shows that the parameter value reaches . The company is currently cutting costs, having completely halted business scaling.
Rincian analitis perusahaan Allakos Inc. (ALLK)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Allakos Inc.|ALLK - Utang jangka dawa marang modal|Utang jangka cendhak marang modal allakos.com|ALLK - Utang perusahaan|Utang-utang marang kapitalisasi buku Allakos Therapeutics|ALLK - Utang jangka dawa perusahaan|Utang jangka cendhak Allakos|Koefisien jangkoan perantara allakos.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ALLK - Penghasilan resik|Penghasilan resik sing dikarepake Allakos Inc.|ALLK - Pangali P/E|Kapitalisasi marang proyeksi bathi allakos.com|ALLK - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Allakos Therapeutics|ALLK - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Allakos|ALLK - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan allakos.com|ALLK - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Allakos Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:ALLK Allakos Inc
The P/S ratio compares the market value of Allakos Inc. (ALLK) to its sales volume, allowing for an assessment of whether the capitalization is fair relative to revenue generation rates. By analyzing the price-to-sales multiple through the lens of antibody development for inflammation therapy, an investor can determine if the potential of the research centers is overvalued, which is critical for ensuring the stability of the invested capital.
Pesaing Allakos Inc.
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|PTGX - Multiplikator P/S|Immunovant, Inc. (IMVT) - Rasio rega marang pendapatan|KNSA (kiniksa.com) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Grifols|Rasio rega marang pendapatan ADPT|Multiplikator P/S CLDX|Multiplikator P/S Aurinia Corp (AUPH)|Rasio rega marang pendapatan BioCryst BCRX|Multiplikator P/S veratx.com VERA|DNTH - Rasio rega marang pendapatan|Rega marang dodolan Pharvaris NV|AbCellera Biologics Inc (ABCL) - Rasio rega marang pendapatan|TRML - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan PGEN|PHAR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NKTR|Koefisien rega marang pendapatan Upstream Bio, Inc.|Rasio rega marang pendapatan Zenas Biopharma, Inc. ZBIO|IMNM: Rasio kapitalisasi marang pendapatan|Gossamer Bio, Inc. - Multiplikator P/S|kalvista.com (KALV) - Kapitalisasi marang pendapatan|SEPN (Septerna) - Kapitalisasi marang pendapatan|PVLA - Koefisien rega marang pendapatan|SVRA (Savara Corp) - Multiplikator P/S|Multiplikator P/S Rigel Corp|Rasio rega marang pendapatan AnaptysBio, Inc. (ANAB)|Rasio rega marang pendapatan ATXS (astriatx.com)|Rasio rega marang pendapatan enGene ENGN|RAPT Therapeutics Inc. - Rasio rega marang pendapatan|JBIO - Rasio rega marang pendapatan|ACRS - Multiplikator P/S|Kyverna Therapeutics (KYTX) - Rasio rega marang pendapatan|Rasio rega marang dodolan TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Multiplikator P/S|VTYX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S THTX|Multiplikator P/S Avalo Therapeutics Inc (AVTX)|Rasio rega marang pendapatan Eledon Pharmaceuticals ELDN|Rasio kapitalisasi pasar marang pendapatan AGEN|CLYM - Rasio rega marang pendapatan|Zura Bio Ltd (ZURA) - Kapitalisasi marang pendapatan|ATYR: Multiplikator P/S|Adagene Inc. (ADAG) - Multiplikator P/S|Kapitalisasi marang pendapatan IMA|STTK: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EQ|Koefisien rega marang pendapatan connectbiopharm.com|Rasio rega marang pendapatan Immunic IMUX|ATRA - Kapitalisasi marang pendapatan|IFRX - Rasio rega marang pendapatan|x4pharma.com (XFOR) - Kapitalisasi marang pendapatan|ACET (adicetbio.com) - Kapitalisasi marang pendapatan|Celularity (CELU) - Multiplikator P/S|Rasio rega marang pendapatan INmune Bio Corp|Rasio kapitalisasi marang pendapatan BRNS (Barinthus Biotherapeutics Corp)|Multiplikator P/S KZR|SABS - Rega marang dodolan|Multiplikator P/S AKTX (Akari Therapeutics Plc)|Multiplikator P/S Enlivex Therapeutics Ltd ENLV|QTTB - Rasio rega marang pendapatan|GOVX: Rasio rega marang pendapatan|Edesa Biotech, Inc. (EDSA) - Rasio rega marang pendapatan|IBIO (ibioinc.com) - Rasio rega marang pendapatan|CARM (Carisma Therapeutics Inc) - Multiplikator P/S|Multiplikator P/S XTL Biopharmaceuticals Ltd|Rasio rega marang pendapatan Bolt Biotherapeutics (BOLT)|Multiplikator P/S hcwbiologics.com (HCWB)|Rasio rega marang pendapatan Aptevo Therapeutics Inc. APVO|AIM ImmunoTech, Inc. (AIM) - Rega marang dodolan|ADTX - Rasio rega marang pendapatan|Koefisien rega marang pendapatan GRI Bio Inc GRI|XRTX (XORTX) - Kapitalisasi marang pendapatan|Vyome Therapeutics - Rasio kapitalisasi pasar marang pendapatan|REVB (Revelation Biosciences) - Multiplikator P/S|indaptusrx.com (INDP) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Scinai Immunotherapeutics Ltd. (SCNI)|calcimedica.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S AFMD (Affimed N.V.)|HOOK - Kapitalisasi marang pendapatan|IGMS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan iteostherapeutics.com ITOS|OCEA: Multiplikator P/S|TC BioPharm (Holdings) Plc (TCBP) - Multiplikator P/S|Rasio rega marang pendapatan Third Harmonic Bio, Inc
